Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;34(12):4385-4392.
doi: 10.1007/s11695-024-07565-y. Epub 2024 Nov 13.

Increased Risk of Hypoglycemia Following Roux-en-Y Gastric Bypass Surgery in Patients Without Diabetes: a Propensity Score-Matched Analysis

Affiliations

Increased Risk of Hypoglycemia Following Roux-en-Y Gastric Bypass Surgery in Patients Without Diabetes: a Propensity Score-Matched Analysis

Eman A Toraih et al. Obes Surg. 2024 Dec.

Abstract

Background: Roux-en-Y gastric bypass (RYGB) surgery is an effective treatment for obesity. However, the incidence and long-term risk of hypoglycemia after surgery in patients without diabetes remains unclear. This study aimed to investigate the prevalence of hypoglycemia following RYGB surgery in patients with obesity and without diabetes.

Methods: A retrospective cohort study was conducted using the TriNetX database. The study population included 15,085 patients with obesity (BMI ≥ 30 kg/m2) who underwent RYGB surgery and 3,200,074 non-surgical controls, all without a history of diabetes or GLP-1 receptor agonist use. Propensity score matching was performed to balance baseline characteristics. The primary outcome was the incidence of hypoglycemia, defined by ICD-10-CM codes or laboratory values (glucose ≤ 70 mg/dL). Cox regression analysis was employed to calculate hazard ratios (HR) and 95% confidence intervals (CI).

Results: In the overall study population, the risk of hypoglycemia was significantly higher in the RYGB group (18.70%, n = 2,810) compared to the control group (3.80%, n = 120,923; HR 4.3, 95% CI 4.14-4.46, p < 0.001). After propensity score matching (n = 14,916 per group), RYGB patients maintained an elevated risk (18.70%, n = 2,795) compared to matched controls (5.0%, n = 749; HR 3.7, 95% CI 3.44-4.05, p < 0.001). Time-series analysis revealed consistently higher hypoglycemia risk in the RYGB group, with hazard ratios ranging from 5.37 (95% CI 4.09-7.03) at 1 week to 3.75 (95% CI 3.45-4.06) at 10 years post-surgery (all p < 0.001). Subgroup analysis of RYGB patients who developed hypoglycemia showed a 30-day hospitalization rate of 21.3% and a mortality rate of 0.71%.

Conclusion: RYGB surgery is associated with a significantly increased risk of hypoglycemia in patients with obesity and without diabetes, both in the short-term and long-term follow-up. These findings underscore the importance of monitoring and managing hypoglycemia in patients undergoing RYGB surgery, even in the absence of preexisting diabetes.

Keywords: Bariatric surgery; Hypoglycemia; Obesity; Propensity score matching; Roux-en-Y gastric bypass.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Prevalence of hypoglycemia in the overall study population before and after propensity score matching. The risk of hypoglycemia was significantly higher in the RYGB surgery group compared to the non-surgical control group, both before and after propensity score matching (p < 0.001)
Fig. 2
Fig. 2
Time-series follow-up of propensity score-matched cohorts. A Incidence of hypoglycemia at various time points following RYGB surgery compared to non-surgical controls. The incidence of hypoglycemia remained significantly elevated in the RYGB surgery group throughout the 10-year follow-up period (all p < 0.001)
Fig. 3
Fig. 3
Risk of hypoglycemia at each time point following RYGB or obesity diagnosis. Cox regression analysis was employed, and hazards ratio (HR) and 95% confidence intervals (CI) are reported. The risk of hypoglycemia remained significantly elevated in the RYGB surgery group throughout the 10-year follow-up period (all p < 0.001)

Similar articles

Cited by

References

    1. Scully T, Ettela A, LeRoith D, et al. Obesity, type 2 diabetes, and cancer risk. Front Oncol. 2020;10: 615375. 10.3389/fonc.2020.615375. - PMC - PubMed
    1. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–48. 10.1152/physrev.00030.2014. - PMC - PubMed
    1. Lohmann AE, Goodwin PJ, Chlebowski RT, et al. Association of obesity-related metabolic disruptions with cancer risk and outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(35):4249–55. 10.1200/JCO.2016.69.6187. - PubMed
    1. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635–43. 10.1038/35007508. - PubMed
    1. González-Muniesa P, Mártinez-González MA, Hu FB, et al. Obesity. Nat Rev Dis Primer. 2017;3(1):17034. 10.1038/nrdp.2017.34. - PubMed